Replies to post #264159 on Avid Bioservices Inc (CDMO)

[biopharm]

Good to have these collaborations but ...MSK and NCCN are being paid for this so very low bar there. AZN is providing drugs but no money. You may have noticed these activities have provided no support for pphm shareprice.

Yes, good to have MSK, NCCN and AstraZeneca and have you read the commends from Dr. Jedd Wolchok expressing his interest on working with PS Targeting/Peregrine? I DOUBT comments like this are said because of a "low bar" and further, there are hundreds of biotechs that are trying to make it so why don't a hundred of them hand over their pipeline drug to NCCN as well and just fork up $2 Million ??

It is because NCCN is required to vet any deal that comes into their 26 cancer hospital network (which includes MSK..) so since MSK had the collaboration first, with Peregrine, MSK had an influence on NCCN picking up PS Targeting.

Its easy to verify the statements by Dr. Jedd Wolchok, all anyone needs to do is look at the PR

-------

"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.

https://globenewswire.com/news-release/2015/05/29/740414/10136438/en/Peregrine-Pharmaceuticals-Enters-Into-Research-Collaboration-to-Investigate-Novel-PS-Targeting-Immunotherapy-Combinations.html

Now that is just the beginning, above.... because after Dr. Jedd Wolchok jumped on board and never received money--- then NCCN jumped all over the opportunity, after they vetted PS Targeting and they didn't have to go far to vet it out...

All they had to do for starters....was ask Dr. Jedd Wolchok and now we know what Dr. Wolchok thinks about PS Targeting

Sounds like he values PS Targeting much more than its current value

Someone will make big money, investing in these price ranges : )